Sign in

CIK 0001875558

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Nuvectis Pharma, Inc.

Sign in to watch
Ticker
NVCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
862405608
Phone
+1 360-837-7232
Business address
1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
  1. 4 Open-market buy Chairman & CEO bought 2,000 shares at $6.40 ($12,800)
  2. 4 Open-market buy Chief Science & Business Off bought 500 shares at $6.29 ($3,145)
  3. 4 Open-market buy Chief Dev. & Ops. Officer bought 1,113 shares at $6.32 ($7,034)
  4. 4 Open-market buy Chairman & CEO bought 5,000 shares at $10.29 ($51,450)
  5. 4 Grant or award Chief Science & Business Off acquired 130,000 shares (grant or award)
  6. 4 Grant or award Chief Dev. & Ops. Officer acquired 130,000 shares (grant or award)
  7. 4 Open-market buy Chairman & CEO bought 640 shares at $11.08 ($7,091)
  8. 4 Open-market buy Chairman & CEO bought 1,080 shares at an average $11.21 ($12,105)
  9. 4 Open-market buy Chairman & CEO bought 3,220 shares at an average $11.01 ($35,455)
  10. 4 Open-market buy Chairman & CEO bought 350 shares at an average $14.61 ($5,112)
  11. 4 Open-market buy Chairman & CEO bought 300 shares at an average $14.73 ($4,418)
  12. 4 Open-market buy 10% owner bought 860 shares at $13.88 ($11,937)
  13. 4 Open-market buy 10% owner bought 2,584 shares at $13.91 ($35,943)
  14. 4 Open-market buy 10% owner bought 1,556 shares at $13.98 ($21,753)
  15. 4 Open-market buy 10% owner bought 10,000 shares at $13.97 ($139,700)
  16. 4 Open-market buy Chairman & CEO bought 335 shares at an average $14.92 ($4,998)
  17. 4 Open-market buy 10% owner bought 8,238 shares at an average $14.47 ($119,224)
  18. 4 Open-market buy 10% owner bought 8,000 shares at $14.84 ($118,720)
  19. 4 Open-market buy Chairman & CEO bought 200 shares at $14.33 ($2,866)
  20. 4 Open-market buy 10% owner bought 9,149 shares at $14.84 ($135,771)

Page 3 of 7 · 139 filings